PRODUCT INFORMATION

Loureirin B

Item No. 27454

CAS Registry No.:	119425-90-0
Formal Name:	1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)-1-propanone
MF:	$C_{18}H_{20}O_5$
FW:	316.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 279 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years
Item Origin:	Plant/Resina Draconis



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Loureirin B is supplied as a solid. A stock solution may be made by dissolving the loureirin B in the solvent of choice, which should be purged with an inert gas. Loureirin B is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of loureirin B in these solvents is approximately 30 mg/ml.

Loureirin B is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, loureirin B should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Loureirin B has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Loureirin B is a flavonoid originally isolated from *D. cochinchinensis*, a major component of the traditional herbal medicine dragon's blood, and has diverse biological activities.[1-3] It inhibits K_v1.3-mediated currents, induces membrane depolarization, and reduces calcium influx in Jurkat T cells.[1] It also inhibits phytohemagglutinin-induced IL-2 release from these cells. Loureirin B (25 µg/ml) reduces type I collagen and fibronectin protein levels in TGF-β1-stimulated fibroblasts as well as contraction of TGF-β1-stimulated fibroblasts in a gel contraction assay.[2] It reduces type I collagen and fibronectin protein levels and inhibits phosphorylation of ERK and JNK in isolated human hypertrophic scar tissue. Loureirin B increases glucose absorption and intracellular ATP levels in Ins-1 cells *via* inhibition of the K_{ATP} current and intracellular influx of calcium.[3]

References

1. Yin, S., Hu, Q., Luo, J., *et al.* Loureirin B, an essential component of *Sanguis Draxonis*, inhibits Kv1.3 channel and suppresses cytokine release from Jurkat T cells. *Cell Biosci.* **4**, 78 (2014).
2. He, T., Bai, X., Yang, L., *et al.* Loureirin B inhibits hypertrophic scar formation via inhibition of the TGF-β1-ERK/JNK pathway. *Cell Physiol. Biochem.* **37(2)**, 666-676 (2015).
3. Sha, Y., Zhang, Y., Cao, J., *et al.* Loureirin B promotes insulin secretion through inhibition of K_{ATP} channel and influx of intracellular calcium. *J. Cell. Biochem.* **119(2)**, 2012-2021 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM